---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-053557"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:09:11.497011+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q3 net loss $58.4M; AbbVie collaboration for RGX-314 with $370M upfront

## Summary
- AbbVie collaboration: $370M upfront, up to $1.38B milestones, 50/50 U.S. profit share.
- Q3 revenue $30.8M (prior year $98.9M included $80M milestone); net loss $58.4M vs prior year net income $8.8M.
- Cash $533.5M; expects to fund operations into H2 2023, excluding AbbVie deal proceeds.
- RGX-314 Phase II: stable visual acuity and reduced anti-VEGF burden in wet AMD; 33% of DR patients improved ≥2 steps.
- IND for RGX-202 for Duchenne muscular dystrophy on track for end of 2021.

## SEC filing metadata
- accession: 0001564590-21-053557
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/0001564590-21-053557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000156459021053557/rgnx-8k_20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-053557
- JSON: https://secwatch.observer/filing/0001564590-21-053557.json
- Plain text: https://secwatch.observer/filing/0001564590-21-053557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.